MedCity News July 28, 2024
The ability to take a drug to market is an important milestone, but it is not the entire picture. To truly move the needle, both clinically and commercially, biopharma companies must fine-tune their teams, approaches and incentives to produce unique and innovative products.
Around 90% of new drugs under investigation fail in clinical trials, but that only tells part of the story. Even among therapies that receive a coveted FDA nod, around 62% underperform commercially during their first year.
This is a complex problem that originates far upstream, when biopharma companies are deciding which assets should advance through their pipelines. At that point, it’s easy to choose therapies with the best chance to achieve FDA approval, but it can...
Today's Sponsors
Today's Sponsor